Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

625
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
625
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

484
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
484
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

524
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
524
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

634
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
634
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

670
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
670
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

561
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[SICOA-GISE Consensus document on carotid atherosclerotic disease: from increased intima-media thickness to stenosis. Diagnostic and therapeutic management].

Giornale italiano di cardiologia (2006)·2026
Same author

Complexity analysis of heart rate variability: application to Holter monitoring in patients with hereditary angioedema due to C1 inhibitor deficiency.

Physiological measurement·2026
Same author

SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-Analysis.

JACC. Advances·2026
Same author

Affairs of the heart: couples coping with cardiac rehabilitation.

Psychology & health·2026
Same author

Behavioural withdrawal during an acute stress test as a marker of psychobiological vulnerability in hereditary angioedema.

Frontiers in immunology·2026
Same author

High-Risk Coronary Plaques and Carotid Duplex Findings in Asymptomatic Patients Undergoing Primary Prevention Assessment.

Journal of cardiovascular development and disease·2026

Related Experiment Video

Updated: Feb 12, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

805

Exercise training in pulmonary arterial hypertension.

Laura Adelaide Dalla Vecchia1, Maurizio Bussotti1

  • 1Department of Cardiology, Istituti Clinici Scientifici Maugeri SpA SB, Istituto di Milano-IRCCS, Milan, Italy.

Journal of Thoracic Disease
|March 31, 2018
PubMed
Summary

Physical and respiratory rehabilitation, including exercise training (ET), shows promise for improving exercise capacity, quality of life, and potentially prognosis in pulmonary arterial hypertension (PAH) patients. ET offers benefits despite potential risks.

Keywords:
Exercisepulmonary hypertension (PH)training

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

961
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.8K

Related Experiment Videos

Last Updated: Feb 12, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

805
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

961
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.8K

Area of Science:

  • Cardiology
  • Pulmonology
  • Rehabilitation Medicine

Background:

  • Pulmonary arterial hypertension (PAH) involves increased pulmonary vascular resistance (PVR) and reduced cardiac output (CO), leading to dyspnea, fatigue, and reduced exercise tolerance.
  • Current PAH therapies improve clinical status but have limited impact on exercise capacity and prognosis.
  • Physical and respiratory rehabilitation, particularly exercise training (ET), is emerging as a potential management strategy for PAH.

Purpose of the Study:

  • To review the pathophysiological mechanisms of functional impairment in PAH.
  • To evaluate the effects of ET on clinical and functional parameters in PAH patients.
  • To discuss patient selection, monitoring, and the potential prognostic benefits of ET in PAH.

Main Methods:

  • Review of existing literature on PAH pathophysiology and exercise training.
  • Analysis of studies reporting on the effects of ET on exercise capacity, quality of life, and muscle function in PAH.
  • Discussion of safety considerations and patient monitoring during ET programs.

Main Results:

  • ET has demonstrated improvements in exercise capacity, quality of life (QoL), and muscle function in PAH patients.
  • Studies indicate positive effects of ET on pulmonary circulation.
  • Despite potential risks, the benefits of ET in PAH management are consistently reported.

Conclusions:

  • Exercise training may play a specific role in managing PAH, improving key functional parameters.
  • Further research is needed to fully elucidate the prognostic impact of ET in PAH.
  • Careful patient selection and monitoring are crucial for safe and effective ET programs in PAH.